Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TherapeuticsMD, Inc. - Common Stock (NQ:TXMD)

1.235 -0.015 (-1.23%)
Streaming Delayed Price Updated: 10:28 AM EDT, Oct 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about TherapeuticsMD, Inc. - Common Stock

< Previous 1 2 Next >
TherapeuticsMD Announces Second Quarter 2025 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces First Quarter 2025 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces Full Year 2024 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces Third Quarter 2024 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces Second Quarter 2024 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces First Quarter 2024 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces Full Year 2023 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces Third Quarter 2023 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces Second Quarter 2023 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces First Quarter 2023 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces Third Quarter 2022 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces Additional $7 Million Private Placement
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces $7 Million Private Placement
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces Second Quarter 2022 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces Expiration of Tender Offer
From TherapeuticsMD, Inc.
Via Business Wire
THERAPEUTICSMD INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TherapeuticsMD, Inc. - TXMD
From Kahn Swick & Foti, LLC
Via Business Wire
TXMD Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of TherapeuticsMD, Inc. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces First Quarter 2022 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million
From TherapeuticsMD, Inc.
Via Business Wire
U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA®
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry Date
From TherapeuticsMD, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.